PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron

• Arpan Acharya,
• Anup S. Pathania,
• Kabita Pandey,
• Michellie Thurman,
• Kendra R. Vann,
• Tatiana G. Kutateladze,
• Kishore B. Challagundala,
• Donald L. Durden,
• Siddappa N. Byrareddy

Affiliations

Arpan Acharya

Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center Omaha Nebraska USA

Anup S. Pathania

Department of Biochemistry and Molecular Biology University of Nebraska Medical Centre Omaha Nebraska USA

Kabita Pandey

Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center Omaha Nebraska USA

Michellie Thurman

Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center Omaha Nebraska USA

Kendra R. Vann

Department of Pharmacology University of Colorado School of Medicine Aurora Colorado USA

Tatiana G. Kutateladze

Department of Pharmacology University of Colorado School of Medicine Aurora Colorado USA

Kishore B. Challagundala

Department of Biochemistry and Molecular Biology University of Nebraska Medical Centre Omaha Nebraska USA

Donald L. Durden

Division of Pediatric Hematology‐Oncology Department of Pediatrics Moores Cancer Center UC San Diego School of Medicine La Jolla California USA

Siddappa N. Byrareddy

Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center Omaha Nebraska USA